Express News | IDEAYA Biosciences Inc : Jefferies Raises Target Price to $60 From $52
Express News | IDEAYA Biosciences Inc : Wedbush Cuts Target Price to $54 From $56
Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating
IDEAYA Biosciences (IDYA) has an average buy rating and price target range of $46 to $69, according to analysts polled by Capital IQ.Price: 43.05, Change: +1.70, Percent Change: +4.11
Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts
IDEAYA Biosciences Is Maintained at Overweight by JP Morgan
IDEAYA Biosciences Is Maintained at Overweight by JP
JPMorgan Raises Price Target on IDEAYA Biosciences to $69 From $65, Maintains Overweight Rating
IDEAYA Biosciences (IDYA) has an average buy rating and price target range of $46 to $69, according to analysts polled by Capital IQ.Price: 39.99, Change: +0.37, Percent Change: +0.92
J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $69
J.P. Morgan analyst Anupam Rama maintains $IDEAYA Biosciences(IDYA.US)$ with a buy rating, and sets the target price at $69.According to TipRanks data, the analyst has a success rate of 47.0% and a
Express News | IDEAYA Biosciences Inc : Mizuho Raises Target Price to $55 From $50
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $55
Mizuho Securities analyst Graig Suvannavejh maintains $IDEAYA Biosciences(IDYA.US)$ with a buy rating, and adjusts the target price from $50 to $55.According to TipRanks data, the analyst has a
Upgraded Outlook on IDEAYA Biosciences Amid Promising Phase 2 Trial Results for IDE397
Express News | IDEAYA Biosciences Inc : JP Morgan Raises Target Price to $69 From $65
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
IDEAYA Biosciences Price Target Raised to $61.00/Share From $53.00 by RBC Capital
IDEAYA Biosciences Price Target Raised to $61.00/Share From $53.00 by RBC
Express News | RBC Capital Maintains Outperform on IDEAYA Biosciences, Raises Price Target to $61
IDEAYA Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 49.84% RBC Capital $53 → $61 Maintains Outperform 07/09/2024 52.3% BTIG $55 → $62 Maintains
Express News | IDEAYA Biosciences Inc : RBC Raises Target Price to $61 From $53
RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $61
RBC Capital analyst Gregory Renza maintains $IDEAYA Biosciences(IDYA.US)$ with a buy rating, and adjusts the target price from $53 to $61.According to TipRanks data, the analyst has a success rate
Why SeaStar Medical Holding Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of SeaStar Medical Holding Corporation (NASDAQ:ICU) fell sharply during Wednesday's session after the company entered into a $10 million registered direct offering of 947,868 shares at $10.55
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Wednesday.Shares of Kura Sushi USA, Inc. (NASDAQ:KRUS) fell sharply in today's pre-market trading
Express News | IDEAYA Biosciences Shares Are Trading Lower After the Company Priced a $263 Million Public Offering of 228,572 Common Shares and Pre-funded Warrants at $35 per Share